Loading...
XWAR
MRC
Market cap121mUSD
Jul 14, Last price  
47.90PLN
1D
-0.52%
1Q
11.29%
Jan 2017
151.71%
IPO
226.28%
Name

Mercator Medical SA

Chart & Performance

D1W1MN
P/E
P/S
0.95
EPS
Div Yield, %
Shrs. gr., 5y
-1.98%
Rev. gr., 5y
2.21%
Revenues
469m
-13.54%
132,171,000147,811,000168,482,000226,593,000263,591,000300,764,000420,410,000540,333,0001,834,174,0001,727,349,000542,512,000469,064,000
Net income
-20m
L-89.69%
7,759,0006,868,00010,019,00010,272,00013,904,0004,927,0007,468,000-2,031,000930,185,000446,865,000-190,786,000-19,676,000
CFO
-86k
L
7,567,0001,922,00012,565,0007,878,00016,614,00023,671,000-8,215,00038,535,000712,469,000503,000,00040,793,000-86,000
Dividend
Jun 29, 20232.5 PLN/sh

Profile

Mercator Medical S.A., together with its subsidiaries, manufactures and distributes disposable medical gloves, dressings, and non-woven fabric products in Europe and internationally. The company offers surgical and protective, sterile examination and protective, and household gloves; glove brackets; and single-use clothing, including caps, masks, gowns, shoe covers, surgical shirts, sleeve protectors, and patient's shirts. It also provides surgical drape sheets; sterile drapes with non-adhesive opening; surgical sets; and accessories, such as apparatus covers, limb protectors, table covers, camera covers, adhesive pockets for surgical instruments, and self-adhesive nonwoven tapes. The company markets its products under the nitrylex, opero, MERCATOR, Ansell, dermagel, santex, comfort, vinylex, iNtouch, ambulance, and ideal brands. It serves beauty; hotels, restaurants, catering, and private cleaning; agri-food; automotive; home and garden; education; and retail industries, as well as medical customers comprising healthcare units, industrial plants, retail chains, and pharmaceutical wholesalers. The company was founded in 1989 and is headquartered in Kraków, Poland. Mercator Medical S.A. operates as a subsidiary of Anabaza RAIF V.C.I.C. Ltd.
IPO date
Nov 21, 2013
Employees
888
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
469,064
-13.54%
542,512
-68.59%
Cost of revenue
378,180
516,150
Unusual Expense (Income)
NOPBT
90,884
26,362
NOPBT Margin
19.38%
4.86%
Operating Taxes
19,044
4,571
Tax Rate
20.95%
17.34%
NOPAT
71,840
21,791
Net income
(19,676)
-89.69%
(190,786)
-142.69%
Dividends
(23,873)
Dividend yield
6.00%
Proceeds from repurchase of equity
(16,269)
BB yield
4.09%
Debt
Debt current
999
932
Long-term debt
9,671
5,641
Deferred revenue
150
156
Other long-term liabilities
1,610
2,732
Net debt
(318,198)
(262,474)
Cash flow
Cash from operating activities
(86)
40,793
CAPEX
(39,067)
(109,654)
Cash from investing activities
33,591
(146,739)
Cash from financing activities
(41,072)
(1,386)
FCF
150,050
87,586
Balance
Cash
326,860
421,804
Long term investments
2,008
(152,757)
Excess cash
305,415
241,921
Stockholders' equity
828,971
951,380
Invested Capital
554,531
769,470
ROIC
10.85%
3.02%
ROCE
10.32%
2.58%
EV
Common stock shares outstanding
9,584
9,770
Price
41.50
-15.91%
49.35
-49.12%
Market cap
397,725
-17.51%
482,171
-50.89%
EV
77,148
220,189
EBITDA
113,003
52,033
EV/EBITDA
0.68
4.23
Interest
832
331
Interest/NOPBT
0.92%
1.26%